## 510(k) SUMMARY: PATRIOT® TransContinental™ M Spacer

Company: Globus Medical Inc.

2560 General Armistead Ave.

Audubon, PA 19403 (610) 930-1800

Contact: Kelly J. Baker, Ph.D

Director, Clinical Affairs & Regulatory

Date Prepared: August 13, 2010

Device Name: PATRIOT® TransContinental™ M Spacer

Classification: Per 21 CFR as follows:

§888.3080 Intervertebral Body Fusion Device

Product Code MAX.

Regulatory Class II, Panel Code 87

Predicate(s): PATRIOT® Lumbar Spacers K072970

SE date January 18, 2008

PATRIOT® TransContinental LLIF Spacers K093242

SE date December 23, 2009

Purpose:

The purpose of this submission is clearance of the PATRIOT® TransContinental® M Spacer, a component of the PATRIOT® family of lumbar interbody fusion spacers.

**Device Description:** 

The PATRIOT® TransContinental® M Spacers are lumbar interbody fusion devices used to provide structural stability in skeletally mature individuals following discectomy. The spacers are inserted using an anterior or lateral approach to the lumbar spine. The PATRIOT® TransContinental® M implants are available in various heights and geometric options to fit the anatomical needs of a wide variety of patients. These spacers are to be filled with autogenous bone graft material. Protrusions on the superior and inferior surfaces of each device grip the endplates of the adjacent vertebrae to resist expulsion.

PATRIOT<sup>®</sup> TransContinental™ M Spacers are made from PEEK radiolucent polymer, with an integrated titanium alloy nut and titanium alloy or tantalum markers, as specified in F2026, F136, F1295, and F560.

## Indications for Use:

PATRIOT® TransContinental™ M Spacers are interbody fusion devices intended for use in patients with degenerative disc disease (DDD) at one or two contiguous levels of the lumbosacral spine (L2-S1). DDD is defined as

Sheet 1 of 2

discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had at least six (6) months of non-operative treatment. In addition, these patients may have up to Grade 1 spondylolisthesis or retrolisthesis at the involved level(s).

The PATRIOT® TransContinental™ M Spacers are to be filled with autogenous bone graft material. These devices are intended to be used with supplemental fixation.

## Performance Data:

Mechanical testing (static and dynamic compression, static and dynamic compression-shear, and subsidence) was conducted in accordance with ASTM F2077 and F2267, the "Guidance for Industry and FDA Staff, Guidance for Spinal System 510(k)s", May 3, 2004, and "Guidance for Industry and FDA Staff, Class II Special Controls Guidance Document: Intervertebral Fusion Device", June 12, 2007. Performance data demonstrate substantial equivalence to the predicate device.

**Basis for Substantial Equivalence:** 

The PATRIOT® TransContinental™ M Spacers are similar to the predicate systems with respect to technical characteristics, performance and intended use. The information provided within this premarket notification supports substantial equivalence to the predicate device(s).







Food and Drug Administration 10903 New Hampshire Avenue Document Control Room – WO66-G609 Silver Spring, MD 20993-0002

Globus Medical, Inc. % Kelly J. Baker, Ph.D. Director, Clinical Affairs and Regulatory Valley Forge Business Center 2560 General Armistead Avenue Audubon, Pennsylvania 19403

DEC - 3 2010

Re: K102313

Trade/Device Name: PATRIOT® TransContinental™ M Spacer

Regulation Number: 21 CFR 888.3080

Regulation Name: Intervertebral body fusion device

Regulatory Class: Class II Product Code: MAX Dated: November 29, 2010

Received: November 30, 2010

## Dear Dr. Baker:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <a href="http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm">http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm</a> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <a href="http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm">http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm</a>.

Sincerely yours,

Mark N. Melkerson

Director

Division of Surgical, Orthopedic

And Restorative Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

Indications for l	Jse Staten	nent		DEC - 3	2010
510(k) Number:			<del> </del>	<u></u>	_
Device Name:	PATRIOT®	TransContin	ental™ M S	pacer	
Indications:					
The PATRIOT® Trintended for use in contiguous levels discogenic back paradiographic studies at least six (6) more may have up to (level(s).	patients with of the lum ain with deg s. These pa nths of non-	n degenerati bosacral sp generation o atients shoul operative tr	ive disc dise bine (L2-S1) f the disc of d be skeleta eatment. In	ase (DDE). DDD confirmed ally mature addition	D) at one or two is defined as by history and e and have had these patients
The PATRIOT® Transport bone graft material fixation.	ansContinent . These de	tal™ M Spa vices are int	cers are to tended to be	be filled v e used wit	vith autogenous th supplemental
Prescription Use (Per 21 CFR §801.	X 109)	OR	Over-Th	e-Countei	r Use
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)					
Concurrence of CDRH, Office of Device Evaluation (ODE)					

(Division Sign-Off)
Division of Surgical, Orthopedic,
and Restorative Devices

510(k) Number K102313

sheet lof 1